BOLT - Long Setup Looking for a break above 14.03, Target 17.43, Target 2 $24.93. , Stop signal 11.87.
−1.83USD
−69.20 MUSD
7.88 MUSD
24.09 M
About Bolt Biotherapeutics, Inc.
Sector
CEO
Randall C. Schatzman
Headquarters
Redwood City
Website
Employees (FY)
100
Founded
2015
FIGI
BBG00N8MY5V9
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BOLT is featured.
Frequently Asked Questions
The current price of BOLT is 1.17 USD — it has increased by 5.41% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Bolt Biotherapeutics, Inc. stocks are traded under the ticker BOLT.
Bolt Biotherapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
BOLT stock is 7.34% volatile and has beta coefficient of 0.84. Check out the list of the most volatile stocks — is Bolt Biotherapeutics, Inc. there?
BOLT earnings for the last quarter are −0.43 USD per share, whereas the estimation was −0.50 USD resulting in a 14.00% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Bolt Biotherapeutics, Inc. earnings.
Bolt Biotherapeutics, Inc. revenue for the last quarter amounts to 2.53 M USD despite the estimated figure of 1.73 M USD. In the next quarter revenue is expected to reach 1.71 M USD.
Yes, you can track Bolt Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BOLT stock has risen by 2.63% compared to the previous week, the month change is a 2.50% fall, over the last year Bolt Biotherapeutics, Inc. has showed a 28.22% decrease.
BOLT net income for the last quarter is −17.90 M USD, while the quarter before that showed −16.26 M USD of net income which accounts for −10.12% change. Track more Bolt Biotherapeutics, Inc. financial stats to get the full picture.
Today Bolt Biotherapeutics, Inc. has the market capitalization of 42.32 M, it has decreased by 3.48% over the last week.
No, BOLT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BOLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bolt Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 100.00 employees. See our rating of the largest employees — is Bolt Biotherapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bolt Biotherapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bolt Biotherapeutics, Inc. stock shows the sell signal. See more of Bolt Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Bolt Biotherapeutics, Inc. future price: according to them, BOLT price has a max estimate of 8.00 USD and a min estimate of 1.25 USD. Read a more detailed Bolt Biotherapeutics, Inc. forecast: see what analysts think of Bolt Biotherapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bolt Biotherapeutics, Inc. EBITDA is −72.86 M USD, and current EBITDA margin is −943.52%. See more stats in Bolt Biotherapeutics, Inc. financial statements.